Stem is trading 5.21% lower at $2.69 in pre-market, with no confirmed new catalyst identified for the October 28 decline.
- No fresh company announcement explaining the pre-market move was identified.
- On October 26, Stem’s board announced a strategic-alternatives review, including a possible sale or merger, with no timetable or assurance of a transaction.
- Third-quarter results are scheduled for after market close on November 5; the decline follows losses in recent sessions.